DiaBeta, Micronase Side Effects Linked To Increased Risk of Pregnancy Complications: Study

  • Written by: Irvin Jackson

The active ingredient in DiaBeta, Micronase and similar gestational diabetes drugs may increase the risk of complications among newborns when the medications are used by pregnant women, according to the findings of a new study. 

Researchers from the University of North Carolina at Chapel Hill and the University of Maryland in Baltimore, found that children born to women given drugs with the active ingredient glyburide during pregnancy were more than 40% more likely to be admitted to the neonatal intensive care unit than the children of women who were not given the drug. The findings were published this week in the medical journal JAMA Pediatrics.

The study involved data on 110,879 women who suffered gestational diabetes mellitus (GDM) as determined by U.S. employer-based insurance claims from January 1, 2000, to December 31, 2011. They found that among those women, 4,82 were treated with glyburide and 4,191 were treated with insulin.

Researchers found that glyburide, compared to insulin, increased the risk of respiratory distress by 63%, hypoglycemia by 40%, birth injury by 35% and there was a 43% increased risk that the child was born larger for his or her gestational age.

“Newborns from privately insured mothers treated with glyburide were more likely to experience adverse outcomes than those from mothers treated with insulin,” the researchers concluded. “Given the widespread use of glyburide, further investigation of these differences in pregnancy outcomes is a public health priority.”

Glyburide, also known as glibenclaimide, is used to treat type 2 diabetes. It belongs to a class of drugs known as sulfonylurea, which increase the amount of insulin released by the pancreas. Drugs using glyburide, including DiaBeta, Micronase, and Glynase, currently have a pregnancy risk rating of category B and Category C, meaning there is no evidence of risk in humans, but that the existence of risks have not yet been ruled out.

The study comes shortly after research published in last month’s issue of the medical journal Obstetrics & Gynecology, which warned that glyburide appeared to cross the placenta to potentially impact a developing fetus.

Researchers in that study found that 79% of the cord blood samples had glyburide levels of less than 10 mg/mL, but 37% of the cord blood samples had levels of the drug that were higher than the levels detected in the mother.

Placenta transport of drugs, where the drug appears to have crossed the placenta to potentially come into contact with a developing fetus, is often the first indicator that a drug may impact the development of an unborn child.

Tags: , , , , , , ,


  1. Natalie Reply

    When I was carrying my baby girl i toke glyburide 1 in the morning n two at night when I would wake up my blood sugar would be 45 to 60. I would have this tingling pain down my back. For about 15 mins I would not be able to move. N my baby was born with a complete heart defeat n pph n she not doing thing a normal 4 year old does. I know some thing went wrong I just do know what. It’s so much more to this store. When need answer too.

  2. Miranda Reply

    5 yrs ago my son was born. I was givin glyburide early within my pregnancy and told it was safer than inslulin. My son was delivered early due to high blood pressure and his size. His shoulder got stuck causing shoulder dystosia, which later led to torticollis. He has also been diagnosed with autism. All of which i was told had nothing to do with the medication.. except now my son is still rapidly gaining weight in areas and the dr.s cannot figure out a reason. As well as developing asthma. My other son just turned 2 i was on insulin with him. He was born full term by c section. He is healthy, happy, growing at a normal rate, with ABSOLUTELY no complicatons!

  • Share Your Comments

  • Have Your Comments Reviewed by a Lawyer

    Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.
  • NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

  • This field is for validation purposes and should be left unchanged.
Contact A Lawyer

Contact A Lawyer

Have A Potential Case Reviewed By An Attorney

  • This field is for validation purposes and should be left unchanged.